Category: Asean

Acronis Cyber Foundation Program and GoDaddy Pro announce the completion of school construction projects in Sierra Leone and Guatemala

SCHAFFHAUSEN, Switzerland, April 17, 2023 (GLOBE NEWSWIRE) — The Acronis Cyber Foundation Program is proud to announce the completion of new school construction in Sierra Leone and Guatemala. In partnership with GoDaddy Inc. (NYSE: GDDY), the company that helps entrepreneurs thrive, both construction projects uphold the Program’s mission to help and empower children with modern educational infrastructure and learning environments.

Fourth acquisition brings traffic signal priority solution to the Miovision platform

ST. PAUL, Minn., April 17, 2023 (GLOBE NEWSWIRE) — Miovision, whose scalable intelligent transportation solutions help cities reduce traffic congestion while improving safety, has acquired Global Traffic Technologies (GTT).

GTT, whose Opticom product line is a market-leading emergency pre-emption and traffic signal priority solution, was one of eight operating companies within the Vontier Corporation, who sold the company to Miovision for US$107 million.

“We’re excited to welcome the team behind GTT’s market-leading priority control solution to Miovision,” said Miovision CEO Kurtis McBride. “By providing green light priority, Opticom can reduce emergency response times by up to 25% and emergency vehicle crashes at the intersection by up to 70% while improving the on-time efficiency of public transit. This acquisition builds on our existing product partnership with GTT and allows us to fully integrate GTT’s solution onto the Miovision platform.”

“Becoming part of Miovision will give our customers access to an expanded suite of solutions for improving safety and optimizing urban transportation,” said Global Traffic Technologies President Terry Griffith. “Further integrating our solution within the Miovision platform will accelerate development and ensure continued improvement of our priority control solution for transit and emergency responders.”

“Miovision is an excellent strategic fit for GTT and this combination will undoubtedly enable both companies to better serve their customers long-term,” said Mark Morelli, President and Chief Executive Officer at Vontier.

GTT customers will continue to be supported by Miovision. The addition of GTT brings the total number of intersections in which Miovision has a presence in North America to nearly 100,000.

Under the terms of the deal, GTT staff will become Miovision employees. With the previous acquisitions of US-based Traffop and Rapid Flow and Miovision’s US-based president and CFO, this brings the company’s presence in the US – a key market – to over 100 people.

About Miovision:
Miovision enables cities to reduce traffic congestion and vehicle emissions while improving public safety through scalable intelligent transportation solutions.

Our AI-powered platform helps communities improve traffic efficiency at the intersection and make roads safer for all types of road users – vehicles, bicycles and pedestrians.

Miovision is headquartered in Kitchener, Canada, and has offices in Germany, Serbia, and the US. Since 2005, our systems have detected over 30 billion vehicles and 1.5 billion pedestrians, assisting nearly 2,000 customers in 63 countries. For more information, visit miovision.com.

About Global Traffic Technologies (GTT)
Global Traffic Technologies is the most trusted name in the traffic management industry, with a 58-year history of unrivaled innovation and leadership. Opticom, its flagship product, dominates the market as the world’s leading provider of priority control solutions, with the largest breadth of deployment in North America – nearly 180,000 intersections and vehicles enabled. These impressive statistics reflect the unwavering reliability and unmatched effectiveness of Opticom’s technology.

About Vontier
Vontier is a global industrial technology company uniting critical mobility and multi-energy technologies and solutions to meet the needs of a rapidly evolving, more connected mobility ecosystem. Leveraging leading market positions, decades of domain expertise and unparalleled portfolio breadth, Vontier enables the way the world moves – delivering smart, safe and sustainable solutions to our customers and the planet. Vontier has a culture of continuous improvement built upon the foundation of the Vontier Business System and embraced by over 8,500 colleagues worldwide. Additional information about Vontier is available on the Company’s website at www.vontier.com.

Media Contact

Tony Florio
Director, Communications
Miovision
media@miovision.com
miovision.com

GlobeNewswire Distribution ID 8808823

April 17, 2023

• Market-leading Philips PACS is now available on AWS for industry-leading availability, reliability, security, and AI-supported workflow enhancements
• Expansion of the collaboration with AWS will support the development and deployment of generative AI applications that further support efficient clinical workflows and enhance diagnostic capabilities

Amsterdam, the Netherlands and Chicago, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology today announced the availability of Philips HealthSuite Imaging on Amazon Web Services (AWS). Additionally, Philips and AWS will build on their relationship, advancing AI in healthcare by applying Foundation Models using Amazon Bedrock to accelerate the development of cloud-based generative AI applications that will provide clinical decision support, help enable more accurate diagnoses, and automate administrative tasks.

The availability of Philips HealthSuite Imaging on AWS is a new addition to Philips’ broad capabilities in enterprise informatics, enabling improved image access speeds, reliability, and data orchestration for radiologists and clinicians across the entire imaging workflow – from diagnosis to therapy selection, treatment and follow-up. Clinicians will be able to access the latest innovations from any location, and healthcare organizations can reduce costs previously invested in on-premises hardware or data centers to host their image management platform.

Philips can help clinicians manage growing workloads amidst staff shortages and speed time to diagnosis and treatment, enhancing patient outcomes. Philips HealthSuite Imaging will use Amazon HealthLake Imaging to increase scale, deliver fast time to first image, enable easy re-use of images for Machine Learning and research, and reduce medical imaging costs.

Philips will also use Amazon Bedrock as part of its efforts to develop generative AI applications to advance PACS image processing capabilities and simplify clinical workflows and voice recognition. Amazon Bedrock will enable Philips to develop Machine Learning-based applications quickly and reduce model development costs versus building Foundational Models (FMs) from scratch or running multiple task-specific model development efforts.

“With healthcare systems under increasing pressure, the focus of clinicians’ has shifted from technical specifications towards more efficient workflows that lead to accurate diagnoses – and that’s what we are delivering here,” said Shez Partovi, Chief Innovation & Strategy Officer and Business Leader Enterprise Informatics at Philips. “By shifting from on-premises to the cloud, we can leverage the security, reliability, and unmatched breadth and depth of AWS to support healthcare organizations in their mission to deliver high quality care while easing the burden on their staff.”

“Healthcare organizations are looking for ways to decrease operational costs, improve health data interoperability, and enable data-driven decision making for clinicians to improve access to quality patient-centered care,” said Swami Sivasubramanian, vice president of database, analytics, and machine learning at AWS. “Through democratizing access to generative AI and applying FMs to help support clinical decision-making, increase diagnostic accuracy, and automate administrative tasks, AWS will continue to support Philips as they uncover new ways to simplify radiologists’ workflow and reduce cognitive burden and clinician burnout.”

Philips and AWS provide migration expertise and planning services, total-cost-of-ownership analysis, and cybersecurity technical expertise to enable an easy migration from on-premises to cloud-based solutions for customers.

To learn more about Philips’ enterprise informatics portfolio, join Philips in person at HIMSS23 at booth #901 or visit Philips’ virtual informatics experience and follow @PhilipsLiveFrom for #HIMSS23 updates throughout the event.

For further information, please contact:

Anna Hogrebe
Philips Global Press Office
Tel.: +1 416 270 6757
Email: anna.hogrebe@philips.com

Joost Maltha
Philips Global Press Office
Tel: +31 6 10 55 8116
Email: joost.maltha@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at http://www.philips.com/newscenter.

Attachments

• Clinicians review a worklist screen with Philips VuePACS
• IntelliSpace PACS Universal Data Manager

GlobeNewswire Distribution ID 1000804279

• To be published on quarterly basis, with updated average sales price (ASP) and National Average Drug Acquisition Cost (NADAC) trends
• Biosimilars continue to play a crucial role in driving down healthcare costs

INCHEON, Korea, April 17, 2023 (GLOBE NEWSWIRE) — Samsung Bioepis Co., Ltd. today released the first edition of its Biosimilar Market Report which explores latest market trends for all biosimilars commercially available in the United States. The first quarterly report details the most recent price trends of all molecules for which biosimilars have launched, along with insights into interchangeability of biosimilars.

“The first edition of Biosimilar Market Report from Samsung Bioepis reveals that market competition stimulated by the introduction of biosimilars in the US has contributed to significant price reductions in the biologics market. However, the level of biosimilar usage varies by molecule, with some still taking less than 50% of the market share. This indicates that there is still room for greater cost savings in therapeutic areas such as supportive care, immunology, and ophthalmology,” said Tom Newcomer, Vice President, Head of Market Access, US, at Samsung Bioepis. “Biosimilars continue to play a crucial role in driving down healthcare costs in the US and we hope this report provides an insightful context into the forefront of the US biosimilar market landscape,” he added.

The key findings of the Report are as follows:

• Increased biosimilar usage is correlated to lower cost, with oncology (trastuzumab, bevacizumab, rituximab) biosimilars being more price sensitive than supportive care (filgrastim, pegfilgrastim, epoetin alfa) or immunology (infliximab).
• On average, biosimilars gained 53% market share three years after their initial launch. Oncology and pegfilgrastim have seen faster acceptance (75%) of biosimilars compared to other therapeutic areas.
• Biosimilar launches have led to significant price decreases over time. ASPs declined 41% on average three years after first biosimilar launch. ASPs for oncology biosimilars experienced the steepest decline, with each dropping over 50% in the first three years after biosimilar launch.
• Insulin glargine and adalimumab categories reflect recent pricing practices such as unbranded biologics and high/low wholesale acquisition cost (WAC) options. The report analyzes national average drug acquisition costs (NADAC) for products under the pharmacy benefit, whose findings indicate the potential for deep discounts and savings in insulin and adalimumab classes.¹

Going forward, Samsung Bioepis Biosimilar Market Report will be published every quarter after the Center of Medicare, Medicaid Services (CMS) publishes updated ASP values for each product. To access the full report, please visit https://www.samsungbioepis.com/upload/attach/SB+Biosimilar+Market+Report+Q2+2023.pdf.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world’s leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, and endocrinology. For more information, please visit: www.samsungbioepis.com and follow us on social media – Twitter, LinkedIn.

References:

¹ There is no ASP data publicly available for products under the pharmacy benefit, so NADAC was used to analyze the net price of products under the pharmacy benefit.

MEDIA CONTACT

Anna Nayun Kim, nayun86.kim@samsung.com

Jane Chung, ejane.chung@samsung.com

GlobeNewswire Distribution ID 8808799

ATLANTA and LIER, Belgium, April 17, 2023 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq: DSGX) (TSX:DSG), announced today that the Descartes eBookings for Ocean Shipment Management solution is now an SAP Endorsed App, available for online purchase on SAP^® Store. SAP Endorsed Apps are a category of solutions from SAP’s partner ecosystem that help customers become best-run, intelligent enterprises. Endorsed apps are meant to deliver value with desired outcomes.

“We’re delighted to announce that Descartes eBookings for Ocean Shipment Management is an SAP Endorsed App,” said Kenneth Wood, Executive Vice President, Product Management at Descartes. “The ability of Descartes eBookings for Ocean Shipment Management to connect carriers across the globe and transform shipment data helps manufacturers, retailers and distributors digitize their supply chain operations.”

SAP Endorsed Apps are premium certified by SAP with added security, in-depth testing and measurements against benchmarks results. Descartes eBookings for Ocean Shipment Management is part of the Descartes Global Logistics Network and is integrated with the SAP Logistics Business Network. The combination expands customers’ ocean shipment management capabilities, uniting multiple parties and processes together from the contract to booking phase through the tracking and financial settlement lifecycle. Descartes eBookings for Ocean Shipment Management is a cloud-based, proven solution that enhances SAP TM via SAP Business Network Freight Collaboration to execute bookings and provide shipment status visibility information.

“Ecosystem innovations are essential to SAP’s vision and delivery of the intelligent enterprise for SAP customers,” said Darryl Gray, Global Vice President, Software Partner Solution Monetization & Success at SAP. “We applaud Descartes on achieving SAP Endorsed App status for the Descartes eBookings for Ocean Shipment Management solution. Partners like Descartes are positioned to help us deliver a cloud-first strategy with integrated innovations, proven to provide value while solving key business challenges.”

The Descartes eBookings for Ocean Shipment Management solution is available for digital discovery and purchase at SAP Store, the digital marketplace for solutions from SAP and its partners. SAP Store provides customers with real-time access to more than 2,000 innovative solutions from SAP as well as partner solutions that complement and extend their SAP applications, enabling digital transformation of their business.

About Descartes

Descartes is the global leader in providing on-demand, software-as-a-service solutions focused on improving the productivity, security, and sustainability of logistics-intensive businesses. Customers use our modular, software-as-a-service solutions to route, track and help improve the safety, performance and compliance of delivery resources; plan, allocate and execute shipments; rate, audit and pay transportation invoices; access global trade data; file customs and security documents for imports and exports; and complete numerous other logistics processes by participating in the world’s largest, collaborative multimodal logistics community. Our headquarters are in Waterloo, Ontario, Canada and we have offices and partners around the world. Learn more at www.descartes.com, and connect with us on LinkedIn and Twitter.

SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see https://www.sap.com/copyright for additional trademark information and notices.

Global Media Contact
Cara Strohack
Tel: +1(800) 419-8495 ext. 202025
cstrohack@descartes.com

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that relate to Descartes’ solution offering and potential benefits derived therefrom; and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the factors and assumptions discussed in the section entitled, “Certain Factors That May Affect Future Results” in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities commissions across Canada including Descartes most recently filed management’s discussion and analysis. If any such risks actually occur, they could materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. We do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

GlobeNewswire Distribution ID 8808217

– Designed to deliver coordinated blockade of PD-1/PD-L1 pathway with targeted, enhanced IL-18 signaling to critical antitumor effector cells –

– T cells co-expressing PD-1 and IL-18 receptors are highly enriched in the tumor microenvironment (TME) versus peripheral blood, providing rationale for tumor-selective targeting with BPT567 –

– Marked expansion of CD8+ T-cells and reduction of regulatory T-cells, with mediation of tumor regression via CD8+ T-cell dependent mechanism(s) –

SAN DIEGO and BASEL, Switzerland, April 17, 2023 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, a biotechnology company developing multifunctional precision immunotherapies for cancer and autoimmune disease, today announced the presentation of new data characterizing the highly targeted biological and therapeutic effects of BPT567 that contribute to its potent single agent anti-tumor activity at the American Association for Cancer Research (AACR) Annual Meeting being held on April 14-19, 2023, in Orlando, FL.

Bright Peak has leveraged its world-class protein engineering capabilities to functionally optimize the master cytokine IL-18, creating an IL-18 binding protein-resistant molecule with enhanced affinity for the IL-18 receptor, and integrate it with PD-1 checkpoint blockade to create a first-in-class PD1-IL18 immunocytokine, BPT567. “BPT567 is designed to coordinately engage antigen-experienced T_eff cells that are known to co-express both PD-1 and the IL-18 receptor. These T-cells have been reported to be highly cytotoxic and enriched in the tumor microenvironment, and as a PD1-IL18 immunocytokine, BPT567 is uniquely targeted to these cells,” said Jon Wigginton, M.D., President of Research and Development of Bright Peak Therapeutics. “Upon further characterization of the biological activity of BPT567 in preclinical tumor models, we found that it was indeed able to more selectively target the potent pro-inflammatory effects of IL-18 to the tumor with limited activation of immune cells in the periphery. It is anticipated that this could ultimately contribute to an improved risk-benefit profile for BPT567 in the clinical setting.”

Details regarding the upcoming AACR abstract presentations are as follows:

April 17, 2023, 9:00 AM – 1:30 PM (EST)
Poster 1850: A First-in-Class PD1-IL18 Immunocytokine (BPT567) Targets PD-1⁺ IL18R⁺ CD8⁺ T Effector Cells Enriched in the Tumor Microenvironment and Exhibits Potent Antitumor Efficacy With Excellent Tolerability

Abstract Highlights: Bright Peak’s unique protein engineering and chemical conjugation platform enables the generation of immunocytokines (ICs) via rapid and site-specific conjugation of optimized cytokines to the Fc domain of existing human antibodies. IL-18 is a master proinflammatory and antitumor cytokine that integrates and stimulates both innate and adaptive immunity and activates antigen-experienced T cells marked by IL-18 receptor (IL-18R) expression, making it an ideal payload to generate an oncology IC. BPT567 is a multifunctional, PD-1 targeted IL-18 based IC consisting of an optimized IL-18 payload with enhanced affinity for IL-18R and significant resistance to the neutralizing factor IL-18 binding protein (IL-18BP), then conjugated to a clinical stage anti-human PD-1 antibody (lipustobart). BPT567 is designed to deliver coordinated PD-1/PD-L1 blockade and IL-18 signaling to the same cell (cis-signaling), with targeting and activation of PD-1⁺ IL-18R⁺ (“double-positive”) CD8⁺ T cells that have been reported to be highly cytotoxic and enriched in the tumor microenvironment (TME).

BPT567 demonstrated significantly greater stimulation of IL-18 induced IFNγ release on PD-1^high versus PD-1^low immune cells in vitro, consistent with cis-signaling-mediated enhancement of potency. In pharmacodynamic (PD) studies performed on MC38 tumor-bearing transgenic mice expressing human PD-1, significant expression of both PD-1 and IL-18R was detected in T cells within the tumor, whereas immune cell populations in the blood expressed low levels of either PD-1 or IL-18R but not both. Detailed characterization revealed that enrichment of simultaneous PD-1 and IL-18R expression occurred principally within CD8 and CD4 memory T cells within the tumor. Accordingly, after BPT567 administration, marked expansion of CD8+ effector memory cells was observed within the tumor with minimal expansion in the blood, while the proportion of regulatory T cells (Tregs) was significantly suppressed in the tumor and unchanged in the blood. Concurrent with these changes in the composition of tumor-infiltrating lymphocytes, BPT567 induced significant release of proinflammatory cytokines within the tumor, including IFNγ, TNF, and GM-CSF, with a far lower extent of cytokine release in the periphery. In preclinical tumor models, administration of BPT567 mediated synergistic antitumor activity that was superior to anti-PD-1 alone, a control non-targeted HER2 IL-18 IC, or the combination of anti-PD-1 and non-targeted IL-18 IC. All mice that were cured of their initial tumors rejected rechallenge with MC38 implantation, confirming the development of long-term immunologic memory induced by BPT567.

The abstract will be made available for viewing on Bright Peak’s website upon presentation at the AACR 2023 Annual Meeting (www.brightpeaktx.com).

About Bright Peak Therapeutics

Bright Peak Therapeutics is a biotechnology company advancing a portfolio of multifunctional immunotherapies for the treatment of patients with cancer and autoimmune disease. We accomplish this by leveraging our world class protein engineering capabilities and our unique cell-free technology platform to chemically synthesize and conjugate novel protein therapeutics that reflect state-of-the-art insights into cytokine and immune checkpoint biology. Our pipeline stretches from discovery to IND-enabling and encompasses antibody-cytokine conjugates and other novel formats. Bright Peak is based in Basel, Switzerland and Del Mar, CA and is funded by a syndicate of leading healthcare investors.

Contact: info@brightpeaktx.com

GlobeNewswire Distribution ID 8808503

Matterport and AWS boost efficiency, safety, and innovation with unified 3D view of business operations

SUNNYVALE, April 17, 2023 (GLOBE NEWSWIRE) — Matterport, Inc. (Nasdaq: MTTR) announced the general availability of new integrations with AWS IoT TwinMaker, enabling enterprise customers to seamlessly connect Internet of Things (IoT) data into visually immersive and dimensionally accurate Matterport digital twins. AWS IoT TwinMaker is a solution from Amazon Web Services (AWS) that makes it easier for developers to create digital twins of real-world systems such as buildings, factories, industrial equipment, and production lines. This new offering from Matterport supports enterprise digital transformation efforts by providing customers with an efficient and cost-effective solution to remotely optimize building operations, increase production output, improve equipment performance, and increase environmental health and safety at their facilities.

“Working with Matterport, we’re now able to provide customers with seamless integration of their live IoT data into detailed, spatially-accurate digital twins,” said Yasser Alsaied, Vice President of IoT, AWS. “There’s an incredible opportunity for enterprise customers to embrace digital twins, especially those in manufacturing, energy, and smart building industries, to gain more insight into their operations while increasing efficiencies across the organization.”

The Matterport and AWS IoT TwinMaker integration is a reflection of the extensive relationship between Matterport and AWS, allowing AWS customers to link real-time operational data into Matterport’s 3D digital twins to simplify the management of complex data sets. Global polymer and chemical manufacturer, INVISTA, one of the world’s largest integrated producers of polymers and fibers, is already using the integration to enable remote monitoring and collaboration, predictive maintenance and virtual training to reduce expenses and significantly increase operational efficiencies.

“With a digital twin of our manufacturing operations, our connected field personnel can proactively enable consistently high performance of our plant assets,” said Jerry Grunewald, Vice President of Operations Transformation, INVISTA. “AWS IoT TwinMaker and Matterport digital twins provide us with a 3D visualization of our facilities for a unified view of live sensor data, equipment maintenance records, and engineering design information that enable us to make effective decisions quickly.”

This integration offers new capabilities to further enable digital twin technology in the enterprise, serving customers at any stage of their digital transformation journey. Real-time operational data is integrated within Matterport’s digital twins to provide a single, unified visual representation of any physical environment and relevant, related data.

Customers using Matterport with AWS IoT TwinMaker can experience several benefits to reduce costs and improve operational efficiencies, including:

• Simplifying the process to create digital representations of physical environments.
• Increasing productivity by enabling consistent high performance of facility assets and streamlining the management of complex data sets.
• Improving field operations in manufacturing plants with real-time IoT sensor and process data.
• Increasing equipment uptime in remote facilities by analyzing trends and predicting issues or maintenance needs.
• Providing remote training and expert instruction to frontline workers.
• Reducing site visits and carbon footprint to realize lower operational costs, sustainability goals, and reduce risk of injury.

“Enterprise businesses are embracing the significant opportunity for digital twins to transform how they manage manufacturing and operational facilities at a global scale,” said RJ Pittman, Chairman and CEO, Matterport. “For environments with heavy machinery, Matterport and AWS have created a new paradigm for managing and training a frontline workforce, creating a safer experience for employees that benefits the bottom line.”

Learn more about how organizations can take advantage of digital twins in their operations: https://matterport.com/partners/amazon-web-services

About Matterport
Matterport, Inc. (Nasdaq: MTTR) is leading the digital transformation of the built world. Our groundbreaking spatial data platform turns buildings into data to make nearly every space more valuable and accessible. Millions of buildings in more than 177 countries have been transformed into immersive Matterport digital twins to improve every part of the building lifecycle from planning, construction, and operations to documentation, appraisal and marketing. Learn more at matterport.com and browse a gallery of digital twins.

©2023 Matterport, Inc. All rights reserved. Matterport is a registered trademark and the Matterport logo is a trademark of Matterport, Inc. All other marks are the property of their respective owners.

Media Contact:
Charlie Stager
Director, Communications
press@matterport.com

Investor Contact:
Mike Knapp
VP, Investor Relations
ir@matterport.com

GlobeNewswire Distribution ID 8808432